CLINICAL TRIALS PROFILE FOR HALOFANTRINE HYDROCHLORIDE

All Clinical Trials for HALOFANTRINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00619944 ↗	Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir	Completed	University of Liverpool	Phase 4	2008-02-01	With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy. Current estimates are that 5-6 million people in sub-Saharan Africa require ART. At the same time, the World Health Organization (WHO) Roll Back Malaria campaign is aggressively promoting the use of artemether/lumefantrine as first-line therapy for malaria in this setting. Many patients in this setting have already become resistant to first-line ARV and have moved onto lopinavir/ritonavir (Kaletra) based second-line regimens. Kaletra is a potent inhibitor of Cytochrome P450 3A4 (CYP 3A4), an enzyme responsible for the metabolism of many drugs which is found predominantly in the liver and the gut. Lumefantrine, and to a lesser extent artemether, is extensively metabolized by CYP 3A4. Therefore when given to a patient already taking Kaletra for HIV, it is likely that elevated levels of these drugs in the patient will result. There is some concern that lumefantrine may be cardiotoxic due to its structural similarity to halofantrine which is known to cause irregular heart rhythms. This has not been borne out as yet in any studies performed with lumefantrine, however it is not known what levels will be achieved in patients when it is administered with a protease inhibitor such as Kaletra. The WHO has not addressed this issue in any of its previous policy documents but has identified ARV-antimalarial drug interaction studies as a research priority. This single dose pharmacokinetic (PK) study aims to compare the levels of lumefantrine/artemether that result when it is given to a patient on Kaletra with patients not on any ARV. Data generated by this study will help address this important knowledge gap which has been identified by WHO and others as meriting urgent investigation.
NCT00619944 ↗	Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir	Completed	Makerere University	Phase 4	2008-02-01	With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy. Current estimates are that 5-6 million people in sub-Saharan Africa require ART. At the same time, the World Health Organization (WHO) Roll Back Malaria campaign is aggressively promoting the use of artemether/lumefantrine as first-line therapy for malaria in this setting. Many patients in this setting have already become resistant to first-line ARV and have moved onto lopinavir/ritonavir (Kaletra) based second-line regimens. Kaletra is a potent inhibitor of Cytochrome P450 3A4 (CYP 3A4), an enzyme responsible for the metabolism of many drugs which is found predominantly in the liver and the gut. Lumefantrine, and to a lesser extent artemether, is extensively metabolized by CYP 3A4. Therefore when given to a patient already taking Kaletra for HIV, it is likely that elevated levels of these drugs in the patient will result. There is some concern that lumefantrine may be cardiotoxic due to its structural similarity to halofantrine which is known to cause irregular heart rhythms. This has not been borne out as yet in any studies performed with lumefantrine, however it is not known what levels will be achieved in patients when it is administered with a protease inhibitor such as Kaletra. The WHO has not addressed this issue in any of its previous policy documents but has identified ARV-antimalarial drug interaction studies as a research priority. This single dose pharmacokinetic (PK) study aims to compare the levels of lumefantrine/artemether that result when it is given to a patient on Kaletra with patients not on any ARV. Data generated by this study will help address this important knowledge gap which has been identified by WHO and others as meriting urgent investigation.
NCT00620438 ↗	Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients	Unknown status	Health Research Board, Ireland	Phase 4	2008-02-01	There are increasing numbers of HIV-infected patients in sub-Saharan Africa receiving antiretroviral drugs and/or rifampicin based antituberculous therapy. HIV infected patients are at an increased risk of contracting malaria. Increasing resistance to anti-malarials such as chloroquine, amodiaquine, fansidar, sulphadoxine-pyrimethamine in East and West Africa has led the WHO to recommend artemether-lumefantrine (Coartem®- Novartis) as first line therapy for malaria for adults and children. As early as 2004, fourteen countries in sub-Saharan Africa had adopted this guideline as national policy. There are no data on the interaction between Coartem® and any of the antiretroviral agents. Both components of Coartem® are substrates for the 3A4 isoform of cytochrome P450. Despite the lack of data, antiretroviral drugs and/or antituberculous drugs in addition to Coartem® are of necessity co-prescribed daily in the African setting. Nevirapine, efavirenz and rifampicin are known inducers of cytochrome P450 3A4. A technical consultation convened by WHO in June, 2004 concluded that additional research on interactions between antiretroviral and antimalarial drugs is urgently needed. We propose to perform a suite of pharmacokinetic studies to evaluate these interactions in HIV infected Ugandan patients. The aim of these studies is to evaluate the pharmacokinetic interaction between Coartem® and commonly co-prescribed inducers of 3A4 i.e. nevirapine, efavirenz and rifampicin. 1. Comparison of steady state pharmacokinetics of Coartem® in HIV-infected patients prior to commencement of nevirapine and at nevirapine steady state 2. Comparison of steady state pharmacokinetics of Coartem® in HIV-infected patients prior to commencement of efavirenz and at efavirenz steady state 3. Comparison of steady state pharmacokinetics of Coartem® in Ugandan patients at rifampicin steady state and without rifampicin

Clinical Trial Conditions for HALOFANTRINE HYDROCHLORIDE

Condition Name

Condition Name for HALOFANTRINE HYDROCHLORIDE
Intervention	Trials
HIV Infections	2
Heart Failure	1
Hepatitis C	1

Condition MeSH

Condition MeSH for HALOFANTRINE HYDROCHLORIDE
Intervention	Trials
Malaria	2
HIV Infections	2
Malaria, Falciparum	1

Clinical Trial Locations for HALOFANTRINE HYDROCHLORIDE

Trials by Country

Trials by Country for HALOFANTRINE HYDROCHLORIDE
Location	Trials
Uganda	2
United Kingdom	2
France	1
Papua New Guinea	1

Clinical Trial Progress for HALOFANTRINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for HALOFANTRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for HALOFANTRINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	6
Unknown status	1

Clinical Trial Sponsors for HALOFANTRINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for HALOFANTRINE HYDROCHLORIDE
Sponsor	Trials
University of Liverpool	2
Makerere University	2
Lihir Medical Centre	1

Sponsor Type

Sponsor Type for HALOFANTRINE HYDROCHLORIDE
Sponsor	Trials
Other	14
U.S. Fed	2
Industry	2

Halofantrine Hydrochloride Clinical Trials Update, Market Analysis, and Exclusivity-to-Competition Projection

Last updated: July 28, 2026

Halofantrine hydrochloride is an antimalarial (quinine-class related) used for uncomplicated malaria where it is marketed. The product’s commercial outlook is constrained by safety-driven restrictions, slow regulatory expansion, and the availability of better-tolerated first-line regimens in many markets. Patent-based exclusivity is not expected to be a primary driver of near-term competition; the dominant competitive forces are guideline positioning, procurement choices, and ongoing availability of alternative artemisinin-based therapies.

What is the current clinical trials and evidence update for halofantrine hydrochloride?

Halofantrine’s clinical footprint is older than contemporary antimalarial development. The most actionable “update” for business planning typically comes from (1) WHO and national guideline inclusion or exclusion, (2) safety review cycles focused on QT prolongation risk, and (3) whether new clinical development is occurring for pediatric dosing, different salt forms, or co-formulation with metabolism-reducing strategies. Public-facing trials activity for halofantrine in recent years is limited compared with newer entrants (artemisinins, fixed-dose combinations, tafenoquine-like agents, and next-generation endoperoxides).

What clinical outcomes drive halofantrine adoption or withdrawal?

Halofantrine efficacy is tied to parasite clearance in uncomplicated malaria, but market use is heavily shaped by safety signals, specifically cardiac risk. The key clinical risk framing used by regulators and guideline bodies is:

• QT interval prolongation and risk of torsades de pointes, particularly with:
  • concomitant QT-prolonging drugs,
  • CYP3A4 inhibitors,
  • higher exposures or dosing deviations,
  • electrolyte disturbances (eg, hypokalemia).

What trial design issues matter for halofantrine stakeholders?

Where newer trial activity exists, it is typically assessed against:

• standardized ECG monitoring for QTc,
• controlled administration conditions (food effects, co-medication restrictions),
• pharmacokinetic exposure targets to avoid high Cmax.

Where is halofantrine most likely to remain relevant clinically?

Most consistent use cases are:

• settings where artemisinin-based regimens are unavailable, unaffordable, or failing,
• geographies with established procurement channels for older antimalarials,
• salvage-use frameworks under national protocols.

How big is the halofantrine hydrochloride market, and where is revenue concentrated?

There is no modern “blue-chip” revenue profile for halofantrine comparable with leading ACTs. Commercial demand tends to be procurement-driven and concentrated in limited markets with specific supply chains. The market is shaped by:

• malaria burden and national treatment guidelines,
• availability of ACTs through donors and national tenders,
• regulator-by-regulator market authorization status,
• the cost of compliance requirements tied to cardiac safety.

What commercial segments exist?

• government and donor procurement (programmatic purchasing),
• private sector sales in markets where distribution persists,
• limited use under second-line or fallback regimens where still authorized.

What drives volume more than price?

For halofantrine, utilization is more sensitive to:

• guideline status (first-line vs fallback),
• access to safer alternatives,
• supply stability and packaging compliance,
• prescriber behavior under QT-risk warnings.

What is the likely market size direction in 2024–2030?

Base-case direction is flat to declining in most markets because:

• first-line therapy has moved to ACTs widely,
• newer single-dose or fixed combinations reduce adherence friction,
• cardiac-risk management creates prescribing barriers.

When does halofantrine lose exclusivity and how does that affect generic entry risk?

Halofantrine hydrochloride is an older small-molecule antimalarial. For business forecasting, the practical exclusivity question is whether any active, enforceable patents remain that can block generics or line extensions in key jurisdictions.

What does “exclusivity” mean for halofantrine in practice?

For older drugs:

• composition-of-matter patents, if they ever existed broadly, are typically expired by now,
• pediatric exclusivity and data exclusivity are usually not relevant without recent regulatory milestones,
• formulation or process patents may have lapsed or are limited in geographic scope.

What does that imply for generic entry risk?

Generic risk is structurally high because:

• older active ingredient use reduces barriers to regulatory replication,
• typical development timelines shrink when no new clinical data is required,
• safety label management often becomes the primary “gate” rather than IP.

Projection (practical): In most markets where halofantrine remains authorized, generic competition is already present or can be expected if supply incentives exist, with delays driven mainly by regulatory maintenance, local registrations, and tender procurement practices rather than enforceable patent life.

What is the Orange Book status of halofantrine hydrochloride and how does it shape US competition?

Halofantrine hydrochloride is not typically associated with an ongoing US brand-to-generic exclusivity narrative like many modern specialties. For US planning:

• US commercial presence is generally limited,
• US exclusivity timelines are usually not the principal factor for competition in regions where halofantrine is already established.

Business implication: US-centric Paragraph IV dynamics are unlikely to be the primary driver for global competitive pricing and availability. Competitive forecasting should instead prioritize non-US markets, tender cycles, and guideline inclusion.

What patent estate could protect halofantrine hydrochloride formulations, dosing, or manufacturing?

Even when composition-of-matter patents expire, secondary IP can sometimes persist:

• solid-state or salt form specifications,
• formulation compositions (excipient systems, release characteristics),
• manufacturing process controls,
• packaging and dosing device-related claims (rare for older antimalarials).

Which formulation IP targets are common for antimalarials?

For quinine-class and related antimalarials, potential claim areas include:

• controlled dissolution or bioavailability tuning,
• food-effect mitigations by prescribing or formulation engineering,
• stability and shelf-life improvements that can support regulatory renewals.

What is the business relevance of formulation patents here?

If halofantrine is already marketed generically in many regions, formulation patents tend to matter only if:

• they are still active in specific countries,
• they materially affect regulatory approval for generics,
• licensing creates cost or timing friction.

Projection (practical): Given the age of the active ingredient, the IP barrier is likely low for entry, and the practical barrier is label conformity plus safety-limited prescribing behavior.

How does halofantrine compare with artemisinin-based combination therapies in competitive positioning?

Why do ACTs crowd out halofantrine?

• ACTs have become the default guideline standard for uncomplicated malaria in many countries,
• safety profiles are generally more favorable,
• procurement pipelines and donor financing prioritize ACTs.

What niche does halofantrine still compete for?

• rescue or fallback therapy in low-access settings,
• specific national procurement arrangements where older antimalarials remain in use.

Competitive landscape snapshot (what to watch)

• Introduction of new ACT fixed-dose combinations with better palatability and adherence,
• National tender contracts shifting to newer regimens,
• Removal of halofantrine from first-line recommendations.

What is the regulatory status and safety framework for halofantrine hydrochloride?

Safety and regulatory labeling around QT prolongation are central to commercial viability:

• contraindications and precautions for known high-risk combinations (QT-prolonging drugs),
• CYP3A4 interaction cautions (food and drug-drug interactions),
• ECG monitoring guidance where appropriate for higher-risk groups.

What regulatory actions tend to change market access?

• tightening contraindications,
• requiring specific counseling or risk minimization measures,
• restricting patient groups.

How do these rules translate into commercial outcomes?

Even with availability of product:

• prescriber adoption decreases when compliance burdens rise,
• wholesalers and distributors face lower turnover in markets that reduce use.

What settlement or litigation risks exist for halofantrine hydrochloride?

For a mature small-molecule antimalarial, halofantrine-specific high-profile patent litigation is not a core planning driver in the way it is for recent biologics or patented oral oncology drugs. If litigation exists in certain jurisdictions, it would more likely involve:

• local formulation or process claims,
• trademark or trade dress disputes,
• regulatory exclusivity contests, which are less typical for older actives.

Projection (practical): Litigation is not expected to be the dominant driver of near-term competition. Guideline position and supply chain factors drive market dynamics more strongly.

What biosimilar risk applies to halofantrine hydrochloride?

None. Halofantrine is a small molecule. The biosimilar framework does not apply.

What generic entry risks exist for halofantrine hydrochloride in key markets?

Generic risks in this context are regulatory registration and market access risks, not Paragraph IV style US exclusivity contests.

What can delay generic market penetration?

• local product registration maintenance,
• quality system upgrades required for GMP compliance,
• safety label alignment and local pharmacovigilance capabilities,
• procurement tenders that lock in incumbents for multi-year periods.

What can accelerate penetration?

• tender requirements that accept multiple suppliers,
• price pressure from ACT oversupply or donor reallocation,
• relief from supply shortages leading to multi-source purchasing.

When is halofantrine projected to grow or decline, and what are the commercial milestones to watch?

Base case projection (2024–2030)

• Market volume: flat to declining in many markets due to guideline standard-of-care shift toward ACTs.
• Value: potentially pressured by generic availability and procurement price resets.
• Use case: increasingly niche as an alternative/fallback where alternatives are limited.

Key milestones that move the curve

• inclusion or removal from national malaria treatment guidelines,
• changes to drug interaction labeling that alter prescribing comfort,
• donor procurement shifts,
• approval of alternative therapies that reduce fallback reliance.

Key Takeaways

• Halofantrine’s commercial future is driven more by guideline positioning and QT-risk labeling than by patent exclusivity.
• Recent “clinical trial updates” are likely limited in public visibility versus newer antimalarials; the practical update cycle is safety/regulatory and guideline-based.
• Generic entry risk is structurally high because the active ingredient is mature, with the primary constraints being regulatory registration and procurement practices.
• Market outlook is flat to declining in most geographies where ACTs dominate first-line treatment.

FAQs

1. Is halofantrine still recommended for uncomplicated malaria in current WHO or national guidelines?
2. What QT-prolongation interactions are most important for halofantrine co-administration risk management?
3. Do halofantrine hydrochloride product labels require food and dosing restrictions that affect real-world use?
4. Which procurement or donor policy changes most directly reduce or increase halofantrine demand?
5. Are there any ongoing reformulation programs targeting halofantrine safety or pharmacokinetics?

References

1. World Health Organization. (n.d.). Malaria treatment guidelines and related guidance documents. WHO.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and related labeling resources. FDA.
3. European Medicines Agency. (n.d.). Product information and assessment reports for antimalarial medicines. EMA.
4. FDA. (n.d.). Safety communications and drug labeling guidance on QT prolongation and drug-drug interactions. FDA.